Neurophet, an AI company specializing in brain disorder diagnosis, will showcase its integrated brain imaging analysis solution, Neurophet AQUA AD Plus, at the 2026 BIO International Convention in San Diego. This tool supports Alzheimer's treatment decisions by analyzing MRI and PET scans throughout the treatment process. Neurophet aims to expand partnerships with global pharmaceutical and biotech firms and introduce its imaging core lab services for clinical trials in Alzheimer's and Parkinson's disease. Participation in BIO USA is expected to accelerate Neurophet's business development and strategic collaborations in the neuroimaging sector.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
